Revolution Medicines Earns Buy as RASONQUE FDA Approval and Strong Pricing Outlook Drive Price Target Increase to $315
Tip Ranks·- LifeSci Capital analyst Charles Zhu maintained a buy rating on Revolution Medicines and raised the price target to 315.00 dollars. - The rating and price target increase are driven by the FDA approval of RASONQUE for metastatic pancreatic cancer, establishing the firm as a commercial-stage company with a strong monthly WAC price of 39,800 dollars. - Additional upside potential is supported by upcoming phase 3 trial results, pipeline expansion, and favorable real-world usage trends across multiple cancer indications.